Insider Transactions in Q1 2025 at Senti Biosciences, Inc. (SNTI)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2025
|
Celadon Partners Spv 24 > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
9,777,000
+50.0%
|
-
|
|
Mar 10
2025
|
New Enterprise Associates 15, L.P. |
BUY
Conversion of derivative security
|
Direct |
3,333,000
+46.89%
|
-
|
|
Mar 10
2025
|
Bayer Healthcare LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,222,000
+44.16%
|
-
|
|
Mar 10
2025
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
BUY
Conversion of derivative security
|
Indirect |
33,000
+50.0%
|
$66,000
$2.25 P/Share
|
|
Mar 07
2025
|
K Lu Timothy CEO and Interim PFO and PAO |
BUY
Grant, award, or other acquisition
|
Direct |
642,358
+47.0%
|
-
|
|
Mar 07
2025
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
78,363
+47.39%
|
-
|
|
Feb 06
2025
|
K Lu Timothy CEO and Interim PFO and PAO |
SELL
Open market or private sale
|
Direct |
545
-0.66%
|
$2,180
$4.36 P/Share
|
|
Feb 06
2025
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
SELL
Open market or private sale
|
Direct |
182
-2.07%
|
$728
$4.37 P/Share
|
|
Feb 04
2025
|
K Lu Timothy CEO and Interim PFO and PAO |
SELL
Open market or private sale
|
Direct |
3,922
-4.53%
|
$15,688
$4.07 P/Share
|
|
Feb 04
2025
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
SELL
Open market or private sale
|
Direct |
1,297
-12.84%
|
$5,188
$4.07 P/Share
|